ReviewHepatology communications2026
Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC.
Review in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancers include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), combined hepatocellular-cholangiocarcinoma (cHCC-CCA), and rarer hepatic malignancies. Their biomarker landscapes differ substantially. HCC has many approved systemic therapies, yet most are still selected through clinical context, liver function, tumor burden, and treatment line. By contrast, iCCA and broader biliary tract cancers (BTCs) have fewer patients but multiple treatment-directing genomic alterations, including FGFR2 fusions or rearrangements, IDH1 mutations, HER2 positivity, BRAF V600E, NTRK or RET fusions, and microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status. cHCC-CCA adds a diagnostic layer because lineage classification and sampling adequacy influence whether HCC-based or BTC-based evidence is more relevant. This review organizes biomarkers by the treatment decision they are expected to support. It covers curative intent and locoregional risk stratification, molecularly guided systemic therapy, immune-state assessment, dynamic monitoring, resistance reassessment, and translational readiness. Across these settings, biomarker value depends on clinical action, evidence maturity, assay feasibility, and timing. The review separates decision-ready markers, trial-enrichment tools, monitoring assays, and mechanistic signatures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.